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Abstract
In a previous study we found that the preferring GluN2A receptor antagonist, NVP-AAM077, elicited rapid
antidepressant-like effects in the forced swim test that was related to the release of glutamate and serotonin in the
medial prefrontal cortex. In the present work we sought to examine the duration of this behavioral effect as well as the
molecular readouts involved. Our results showed that NVP-AAM077 reduced the immobility in the forced swim test
30 min and 24 h after its administration. However, this effect waned 7 days later. The rapid antidepressant-like response
seems to be associated with increases in the GluA1 subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors, mammalian target of rapamycin (mTOR) signaling, glia markers such as glial fibrillary acidic protein
(GFAP) and excitatory amino acid transporter 1 (EAAT1), and a rapid mobilization of intracellular stores of brain-derived
neurotrophic factor (BDNF) in the medial prefrontal cortex.
Introduction
N-methyl-D-aspartate (NMDA) receptor antagonists
have emerged as central players in the pathophysiology
and treatment of depression1. In particular, ketamine has
revolutionized the pharmacotherapy of mood disorders
because of its rapid and robust therapeutic benefits in
major depressive disorder and bipolar disorder2–6. Pre-
clinical studies have also demonstrated that the anti-
depressant response of ketamine is dependent on the
stimulation of α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptors by released glu-
tamate7–10 and needs activation of the mammalian target
of rapamycin (mTOR) pathway11. Interestingly, the sus-
tained antidepressant effects of ketamine require an intact
serotonergic transmission in the brain12 and are paralleled
by increases in the outflow of glutamate13, serotonin14,
noradrenaline15 and dopamine16 in the medial prefrontal
cortex (mPFC). However, ketamine is not devoid of
adverse psychotomimetic effects and hence, intense
research focused in investigating whether subtype-
selective NMDA receptor antagonists could possess
improved therapeutic profile. NMDA receptors are het-
erotetrameric complexes assembled from two essential
GluN1 subunits and two GluN2A or GluN2B subunits. In
the mammalian brain, the distribution of such subunits
changes across development and, in adulthood, GluN2A
and GluN2B receptor subunits are predominant in the
neocortex and hippocampus17–19.
Preclinical work has shown that the GluN2B receptor
antagonist, Ro 25-6981, exhibits antidepressant-like
effects in rodents7,11. In the clinic, fewer of these inves-
tigational drugs, CP-101,60620 and CERC-30121
–formerly MK0657–have shown only partial efficacy in
the treatment of depression. However, the antidepressant
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effects of such compounds are meager in comparison with
ketamine and recently CERC-301 failed to demonstrate
antidepressant efficacy on the primary endpoint measure.
On the other hand, inactivation of the GluN2A subunit
has also been shown to evoke antidepressant-like activity
in mice22.
In a previous study, we demonstrated that the selective
GluN2A-preferring receptor antagonist, NVP-AAM077,
elicited rapid antidepressant-like effects in the forced
swim test (FST) in a dose-dependent manner23. In addi-
tion, this effect was associated with increased glutamate
and serotonin efflux in the mPFC. In contrast to ketamine,
an antagonist binding to the phencyclidine binding site in
the channel of NMDA receptors with an IC50 of
350 nM24, NVP-AAM077 potently binds to the glutamate
binding site, with an IC50 of 8 nM
25. In the present study
we sought to examine the changes in intracellular sig-
naling pathways and synaptic protein synthesis produced
by NVP-AAM077 and whether the antidepressant-like
effects in the FST were persistent or short-lasting.
Materials and methods
Animals and treatments
Male Sprague–Dawley rats (Envigo, Sant Feliu de
Codines, Spain) weighing 280–350 g were used. The rats
were maintained in a controled environment (12 h light/
dark, 22 ± 1 °C) where food and water were always avail-
able. All the experimental procedures were conducted in
accordance with the ARRIVE guidelines, national (RD 53/
2013) and European legislation (Directive 2010/63/EU, on
the Protection of Animals Used for Scientific Purposes, 22
September 2010), and were approved by the Institutional
Animal Care and Use Committee of the University of
Cantabria.
NVP-AAM077 was obtained from Novartis (Basel,
Switzerland) and dissolved in 0.1M NaOH. Then the pH
was adjusted to ~7 with 0.1M HCl and taken to a final
dilution with distilled water. The drug was injected
intraperitoneally, at the doses of 10 or 20mg/kg, 30 min
before FST at a volume of 2 ml/kg body weight. Appro-
priate vehicle was injected to controls.
Forced swim test (FST)
Rats were handled daily for 1 week before FST. On day 1
(pretest), rats were placed in a clear plexyglas cylinder
(46 cm height, 30 cm diameter) filled with 24 ± 1 °C water
to a height of 30 cm, for 15min. After this pretest, animals
were returned to their home cage and dried under a lamp
for 30min. The test was conducted 24 h after the pretest
session in the same cylinder for 5 min. The entire 5-min
test session was divided into 5-s epochs. At the end of
each epoch the predominant behavior was rated as
immobility, climbing and swimming by an experimenter
blind to the treatment. In order to examine the duration
of the antidepressant-like effects of a single dose of NVP-
AAM077, the FST was conducted 30min, 24 h and 7 days
after drug administration.
Protein extraction and Western blotting
In a separate experiment, 30 min, 1 and 2 h after the
administration of 10 mg/kg of NVP-AAM077, animals
were killed by decapitation, their brains removed from the
skulls, and mPFCs dissected out on ice and rapidly stored
at −80 °C. For total cell lysate, mPFC samples were
homogenized (1:15) in a solution containing 10mM
HEPES–HCl (pH 7.9), 1.5 mM MgCl2, 100mM KCl, and
the following protease and phosphatase inhibitors: 1 mM
phenylmethylsulfonyl fluoride (PMSF), 0.2 mg/ml aproti-
nin, 10 μg/ml leupeptin, 10 μg/ml pepstatin A, 10 μg/ml
antipain, 10 μg/ml chymostatin, 1 mM Na3VO4, 1 mM
NaF, 1 mM cantharidin and 1 μM E-64. Then, homo-
genates were sonicated on ice in protein lysis buffer
(homogenization buffer containing 1% Igepal®, 0.5%
sodium deoxycholate, 0.1% SDS and 2.5 mM CHAPS) for
30min. Solubilized proteins were recovered in the
supernatant after centrifugation at 14,000×g for 10 min at
4 °C. Protein quantification was performed according to
the Lowry method. The following primary antibodies were
examined: protein kinase B (PKB/Akt), extracellular
signal-regulated kinase (ERK, including ERK1 and ERK2),
cyclic adenosine monophosphate response element-
binding protein (CREB), synapsin I, postsynaptic density
protein 95 (PSD-95), GluA1 subunit, brain-derived neu-
rotrophic factor (BDNF), glial fibrillary acidic protein
(GFAP), excitatory amino acid transporter 1 (EAAT1),
mTOR, eukaryotic initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1), p70 ribosomal S6 kinase (p70S6K)
and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Sixty micrograms of protein for each sample (in
duplicate) were loaded into 8.5–15% SDS-PAGE gel and
transferred to nitrocellulose membranes and incubated
with primary antibodies overnight at 4 °C. The sources
and dilution of primary antibodies used were: rabbit
anti-pAkt (1:1000), rabbit anti-pmTOR (1:250), mouse
anti-mTOR (1:1000), rabbit anti-pp70S6K (1:500), rabbit
anti-p70S6K (1:500), rabbit anti-p4E-BP1 (1:250), rabbit
anti-4E-BP1 (1:500), mouse anti-GFAP (1:1000) and rab-
bit anti-synapsin I (1:1000) from Cell Signaling Technol-
ogies, Inc. (Danvers, MA, USA); rabbit anti-pCREB
(1:500) from Merck Milllipore (Billerica, MA, USA);
mouse anti-GAPDH (1:2000), mouse anti-Akt (1:1000),
rabbit anti-ERK1/2 (1:3000), rabbit anti-BDNF (1:250),
goat anti-PSD-95 (1:500) and rabbit anti-EAAT1 (1:500)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
mouse anti-pERK (MAPK) (1:1000) from Sigma-Aldrich
(St. Louis, MO, USA); and rabbit anti-CREB (1:1000), and
rabbit anti-GluA1 (1:700) from Abcam (Cambridge, UK).
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The next day, membranes were washed with a mixture of
Tris buffered saline and 0.05% Tween 20 and incubated
with fluorochrome conjugated anti-rabbit, anti-mouse or
anti-goat secondary antibodies from Li-Cor Biosciences
(Lincoln, NE, USA). Secondary antibodies were detected
with an Odyssey CLx Scanner, also from Li-Cor
Biosciences (Lincoln, NE, USA). Blot quantitation was
performed by using Image Studio Lite software from
Li-Cor Biosciences (Lincoln, NE, USA), and densitometry
values were normalized with respect to the values
obtained with anti-GAPDH antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA).
Statistics
Data are expressed as mean ± SEM. FST data were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by post hoc Newman–Keuls multiple comparisons
test. In Western blot data, differences with respect to the
respective control group were tested using Student’s t-test
(two-tailed). When more than two groups were com-
pared, protein concentration was assessed by ANOVA
followed by post hoc Newman–Keuls multiple compar-
isons test. In all cases the level of significance was set at P
< 0.05.
Results
Antidepressant-like effects of NVP-AAM077 in the FST
The administration of NVP-AAM077 had significant
effects on immobility (F2,13= 11.98, P < 0.005), climbing
(F2,12= 6.762, P < 0.02) and swimming (F2,13= 6.127,
P < 0.02) behaviors measured in the FST performed
30min later (Fig. 1a). Post hoc comparisons showed that
both doses of the compound (10 and 20mg/kg) reduced
immobility and increased swimming, whereas only the
dose of 10 mg/kg increased climbing. When FST was
conducted 24 h after administration (Fig. 1b), NVP-
AAM077 produced significant effects only on immobi-
lity (F2,15= 8.96, P < 0.005). No apparent antidepressant-
like effects in the FST were noted 7 days after drug
administration (Fig. 1c).
Changes in synaptic proteins and intracellular signaling
after NVP-AAM077
Synaptic fields were identified with the presynaptic
vesicle marker, synapsin I, and the postsynaptic density
marker, PSD-95. NVP-AAM077 decreased substantially
(P < 0.02, Student’s t-test) but transiently (only 30 min
after administration) the synthesis of synapsin I (Fig. 2a,
b). However, no change was observed in the concentra-
tion of PSD-95 (Fig. 2a, c). Interestingly, NVP-AAM077
elevated the expression of the GluA1 subunit of AMPA
receptor (P < 0.05, Student’s t-test) although this was
observed only 30min after the administration of the drug
(Fig. 2a, d). At the dose of 10 mg/kg, NVP-AAM077 did
not alter the active forms of pAkt, pERK and pCREB
(Fig. 2f–h). Total Akt, ERK and CREB levels remained
unchanged (Fig. 2e).
Changes in BDNF and glial markers after NVP-AAM077
As shown in Fig. 3b, NVP-AAM077 induced an early
50% decrease in the level of BDNF protein 30 min after its
administration (P < 0.04, Student’s t-test), but a delayed
increase 2 h later (P < 0.03, Student’s t-test).
Acute administration of 10 mg/kg NVP-AAM077
increased the concentration of GFAP, but only
Fig. 1 Antidepressant-like action of NVP-AAM077 in the forced swim
test (FST) conducted 30 min (a), 24 h (b) and 7 days (c) after its
intraperitoneal administration. Results expressed as mean ± SEM of N
= 5–6 rats/group, *P < 0.05, Newman–Keuls test following significant
one-way ANOVA
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transiently 30 min later (P < 0.05, Student’s t-test; Fig. 3c).
On the other hand, NVP-AAM077 increased the level
of EAAT1 30min (P < 0.02, Student’s t-test) and 1 h
(P < 0.03, Student’s t-test) after administration (Fig. 3d).
Role of mTOR pathway in the antidepressant-like effects of
NVP-AAM077
In order to study whether the antidepressant-like effects
of NVP-AAM077 depended on the activation of the
mTOR intracellular signaling, we administered the mTOR
inhibitor, temsirolimus, at a dose (1 mg/kg, i.p.) known to
block mTOR complex in vivo26 20 min before vehicle or
NVPAAM077. One-way ANOVA revealed significant
main effect of treatment on immobility (F3, 23= 9.77,
P < 0.0005) and swimming (F3, 23= 11.80, P < 0.0001).
Thus, our results showed that blockade of mTOR
suppressed the antidepressant-like response of NVP-
AAM077 (Fig. 4a).
Further, one-way ANOVA showed that temsirolimus
and/or NVP-AAM077 had a significant effect on the
Fig. 2 Effects of NVP-AAM077 (NVP, 10mg/kg) and vehicle (Veh) on the concentration of synaptic proteins and intracellular signaling
pathways in the mPFC at 30min, 1 h, and 2 h after its intraperitoneal administration. a and e Western blots, b synapsin I, c PSD-95, d GluA1, f
phospho-Akt, g phospho-ERK and h phospo-CREB. Results expressed as mean ± SEM of N= 4–6 rats/group, *P < 0.05, two-tailed Student’s t-test
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concentration of pmTOR (F3,16= 4.04, P < 0.03, Fig. 4c),
pp70S6K (F3,15= 5.36, P < 0.01, Fig. 4d) and p4E-BP1
(F3, 16= 6.38, P < 0.005, Fig. 4e). Therefore, our results
showed that NVP-AAM077 increased the level of pmTOR
(P < 0.05, Newman–Keuls test), an effect blocked by
temsirolimus (P < 0.05, Newman–Keuls test). Temsir-
olimus also reduced the synthesis of pp70S6K both in
vehicle-treated (P < 0.05, Newman–Keuls test) and NVP-
AAM077-treated (P < 0.05, Newman–Keuls test) rats.
Finally, NVP-AAM077 reduced the level of p4E-BP1 (P <
0.05, Newman–Keuls test) both in vehicle-pretreated and
in temsirolimus-pretreated rats. Total mTOR, p70S6K
and 4E-BP1 levels remained unchanged.
Discussion
In a previous work from our lab, we demonstrated that
the blockade of the GluN2A subunit of the NMDA
receptor with NVP-AAM077 exhibited antidepressant-
like effects in the FST, in the absence of potential psy-
chotomimetic effects23. Here we extend those results
showing that these effects can last a maximum of 24 h, but
vanished 7 days after a single intraperitoneal administra-
tion of this drug. As suggested by Cryan and coworkers27,
the increase in swimming behavior after NVP-AAM077
can be attributed to the enhanced release of serotonin in
the mPFC that we observed previously23. It could be
argued that NVP-AAM077 is not fully specific for the rat
GluN2A subunit, and prefers rat GluN2A over GluN2B by
a factor of 5–10 only28. The exact mechanism by which
NVP-AAM077 achieves this preference remains unclear,
despite the availability of its crystal structure with the
ligand-binding domain of GluN1-GluN2A NMDA
receptors, in complex with glycine as a co-agonist29.
However, the difference between the effects of NVP-
AAM077 and Ro 25-6981 (full antagonist for NMDA
receptors containing the GluN2B subunit30) on cortical
glutamatergic and serotonergic transmission23, supports
the view of a preferential blockade of the GluN2A subunit
under the present conditions.
The rapid antidepressant-like action of NVP-AAM077
does not seem to rely upon the activation of the Akt, ERK
or CREB signal transduction pathways as is the case for
ketamine11. Rather, it appears more likely to be dependent
on the synthesis of the GluA1 subunit of AMPA receptor,
mTOR and the glial markers, EAAT1 and GFAP, which
were upregulated as soon as 30min after NVP-AAM077.
Therefore, the increase in mTOR after NVP-AAM077 is
an apparent contrast with the lack of up-regulation of
ERK and/or Akt, the usual upstream mediators, and
contrary to what has been found with ketamine11. How-
ever, two other sources of mTOR activation—indepen-
dent of Akt and/or ERK—have been described (Fig. 5).
First, a phospholipase C (PLC)-driven mechanism
including the formation of Ca2+/calmodulin-dependent
protein kinase31. Second, blockade of the NMDA
receptor-induced nitric oxide (NO) synthesis that usually
inhibits the guanosine triphosphatase Rheb32, which is a
positive regulator of mTOR activity.
Fig. 3 Effects of NVP-AAM077 (NVP, 10mg/kg) and vehicle (Veh)
on BDNF, GFAP and EAAT1 in the mPFC at 30min, 1 h, and 2 h
after its intraperitoneal administration. a Western blots, b BDNF, c
GFAP and d EAAT1. Results expressed as mean ± SEM of N= 4–5 rats/
group, *P < 0.05, two-tailed Student’s t-test
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Higher total abundance of GluA1 has been also
observed after ketamine exposure, which might be
responsible of increased excitatory postsynaptic current
amplitude in hippocampal slices11,33. Thus, the fast exci-
tatory neurotransmission through GluA1-containing
AMPA receptors in mPFC—and possibly in the hippo-
campus—would contribute to the antidepressant-like
effects of NVP-AAM077. As a matter of fact, mice
with deletion of the GluA1 subunit exhibit a
depressive-like behavior34, and mRNA coding for
GluA1 is reduced in rats exposed to chronic stress and
also in human hippocampal tissue from depressed
patients35. In addition, chronic antidepressant treatment
in rodents elevates the expression of GluA1 subunit in the
brain36,37.
Postmortem studies have provided compelling evidence
that depressed patients show a decrease in the density
and number of glial cells in prefrontal cortex38,39, which
is associated with a reduction of astrocytic markers,
such as GFAP40 and EAAT141. Further, these changes are
reversed by antidepressant treatment42. However, pre-
clinical studies have yielded contradictory results. Thus,
while one work has demonstrated that a reduction of
astrocytes in the mPFC is sufficient to induce depressive-
like behaviors43, other study has shown that infralimbic
glial lesion did not result in changes in the FST44. It is
possible that differences in the prefrontal site of infusion
may account for such discrepancies. On the other hand, it
has been reported recently that reduction of glial gluta-
mate uptake through blockade of EAAT2 transporter in
Fig. 4 The effect of NVP-AAM077 (NVP) is prevented by temsirolimus. a The decrease in immobility and increase in swimming elicited by NVP-
AAM077 (10 mg/kg) are prevented by pretreatment with temsirolimus (1 mg/kg) 20 min before. b Western blots. c Effects of temsirolimus and/or
NVP-AAM077 on pmTOR. d Effects of temsirolimus and/or NVP-AAM077 on pp70S6K. e Effects of temsirolimus and/or NVP-AAM077 on p4E-BP1.
Results expressed as mean ± SEM of N= 4–6 rats/group, *P < 0.05, Newman–Keuls test following significant one-way ANOVA
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the infralimbic cortex results in antidepressant-like
effects45. In our present work, the increased formation
of GFAP and EAAT1 caused by NVP-AAM077 might be
related to an improved homeostasis of glutamate trans-
mission in the mPFC (disrupted in depression46) that
could also contribute to the rapid antidepressant-like
effects observed in the FST. The rapid, increased synthesis
of postsynaptic GluA1 and mTOR is not accompanied by
parallel changes in PSD95, which seems to suggest that
the transient elevation of GluA1 synthesis might implicate
incorporation of AMPA receptors to synapse—thus
favoring synaptic transmission of glutamate47—in the
absence of an extra synthesis of PSD-95. Alternatively, it is
also possible that changes in PSD-95 can occur after 2 h11
in response to the increased GluA1 synthesis. Another
component possibly involved in the rapid increase of
glutamate transmission after NVP-AAM07723 is the
reduction of synapsin I. It is well known that synapsin I
forms an envelope that coats synaptic vesicles, which
renders them unavailable for release48. Thus, removal of
this cover (expressed in the present work as a rapid
reduction of the concentration of synapsin I) would also
promote release of glutamate in the mPFC49, ultimately
binding to AMPA receptors and leading to the anti-
depressant response. Interestingly, temsirolimus was able
to block the NVP-AAM077-evoked, but not the basal
synthesis of mTOR, an effect also observed by others26,
for which we cannot provide an obvious explanation.
Taking into account that the usual downstream effectors
of mTOR are p70S6K and 4E-BP1, our results indicate
that the rapid antidepressant-like effects of NVP-
AAM077 appear to result from an inhibition of p4E-
BP1, thus leading to a disinhibition of eukaryotic trans-
lation initiation factor 4E (eIF4E) and posterior protein
synthesis, rather than an increase in pp70S6K. CREB is
upregulated and activated in the hippocampus by some,
but not all, chronic antidepressant treatments50, which
suggests, on the one hand, that the relationship between
CREB activation and antidepressant action is region-
dependent and, on the other hand, that requires a sus-
tained antidepressant treatment51. Thus, it is also possible
that CREB signaling occurs later after NVP-AAM077
administration and contributes to keeping delayed
antidepressant-like effects.
Upregulation of BDNF is one of the most compelling
findings associated with antidepressant treatments
although this effect is dependent upon the brain region
and duration of treatment52. Usually, the synthesis of
BDNF mRNA is a process that takes weeks53 and, within
the forebrain, BDNF has been largely associated with
neuronal survival and the regulation of synaptic plasticity.
Therefore, our results rather support the view that BDNF
Fig. 5 Scheme of the proposed intracellular signaling pathways involved in the effects of NVP-AAM077 (NVP). NVP would block NMDA
receptors in GABA interneurons, thus inducing a disinhibition of glutamate release23. Glutamate would evoke a rapid stimulation of AMPA receptors
(AMPAR) localized to plasma membrane of pyramidal cells, which would result in a rapid intracellular activation of Ca2+/calmodulin-dependent
protein kinase II31 that would eventually activate mTOR pathway. On the other hand, the direct blockade of NMDA receptor-induced synthesis of
nitric oxide (NO) by NVP could also activate mTOR pathway. Downstream mediators of mTOR would be responsible for the induction of protein
synthesis, thus increasing the dendritic synthesis of GluA1. Further, the rapid release of BDNF accounted for by the increased intracellular Ca2+ would
possibly be responsible for the rapid antidepressant-like action of NVP
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protein is rapidly utilized after NVP-AAM077, and this is
followed by a compensatory increased synthesis 2 h later.
Also, the elevated utilization of BDNF might be possibly
associated with the increased synthesis of the GluA1 subunit
and its insertion in the postsynaptic membrane54.
Overall, our results suggest that NVP-AAM077 pos-
sesses a unique mechanism of action through the activa-
tion of different signaling pathways ultimately leading to
synthesis of proteins relevant to synaptic plasticity and
antidepressant effects. A rapid mobilization of BDNF
stores and increases in GluA1, mTOR and the astrocytic
markers GFAP and EAAT1 would be responsible for the
initiation of a rapid antidepressant response of NVP-
AAM077.
Acknowledgements
M.G.-S. was recipient of a contract from the Sistema Nacional de Garantía
Juvenil co-funded by the European Social Fund. We also thank Novartis for the
generous gift of NVP-AAM077. This work was supported by the Instituto de
Salud Carlos III, Subdirección General del Evaluación y Fomento de la
Investigación (FIS Grants PI13/00038 and PI16/00217) that were co-funded by
the European Regional Development Fund (‘A way to build Europe’). Funding
from the Centro de Investigación Biomédica en Red de Salud Mental
(CIBERSAM), Instituto de Salud Carlos III is also acknowledged.
Author details
1Instituto de Biomedicina y Biotecnología de Cantabria, IBBTEC (CSIC,
Universidad de Cantabria), Santander, Spain. 2Centro de Investigación
Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III,
Madrid, Spain. 3Departamento de Fisiología y Farmacología, Facultad de
Medicina, Universidad de Cantabria, Santander, Spain. 4Novartis Institutes for
Biomedical Research, Basel, Switzerland
Conflict of interest
Dr. Yves Auberson is Executive Director, Global Discovery Chemistry at Novartis
Institutes for Biomedical Research, the provider of NVP-AAM077. The other
authors declare no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 16 October 2017 Revised: 6 February 2018 Accepted: 18 February
2018
References
1. Skolnick, P., Popik, P. & Trullas, R. Glutamate-based antidepressants: 20 years on.
Trends Pharmacol. Sci. 30, 563–569 (2009).
2. Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients.
Biol. Psychiatry 47, 351–354 (2000).
3. Zarate, C. A. Jr et al. A randomized trial of an N-methyl-D-aspartate antagonist
in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864
(2006).
4. aan het Rot, M. et al. Safety and efficacy of repeated-dose intravenous
ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139–145
(2010).
5. DiazGranados, N. et al. A randomized add-on trial of an N-methyl-D-aspartate
antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67,
793–802 (2010).
6. Singh, J. B. et al. A Double-blind, randomized, placebo-controlled, dose-
frequency study of intravenous ketamine in patients with treatment-resistant
depression. Am. J. Psychiatry 173, 816–826 (2016).
7. Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of
ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
receptors. Biol. Psychiatry 63, 349–352 (2008).
8. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural
antidepressant responses. Nature 475, 91–95 (2011).
9. Koike, H., Iijima, M. & Chaki, S. Involvement of AMPA receptor in both the rapid
and sustained antidepressant-like effects of ketamine in animal models of
depression. Behav. Brain Res. 224, 107–111 (2011).
10. Akinfiresoye, L. & Tizabi, Y. Antidepressant effects of AMPA and ketamine
combination: role of hippocampal BDNF, synapsin, and mTOR. Psycho-
pharmacol. (Berl.). 230, 291–298 (2013).
11. Li, N. et al. mTOR-dependent synapse formation underlies the rapid anti-
depressant effects of NMDA antagonists. Science 329, 959–964 (2010).
12. Gigliucci, V. et al. Ketamine elicits sustained antidepressant-like activity via a
serotonin-dependent mechanism. Psychopharmacol. (Berl.). 228, 157–166
(2013).
13. Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic
neurotransmission by ketamine: a novel step in the pathway from NMDA
receptor blockade to dopaminergic and cognitive disruptions associated with
the prefrontal cortex. J. Neurosci. 17, 2921–2927 (1997).
14. Amargós-Bosch, M., López-Gil, X., Artigas, F. & Adell, A. Clozapine and olan-
zapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal
cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol. 9,
565–573 (2006).
15. Lorrain, D. S. et al. Group II mGlu receptor activation suppresses nor-
epinephrine release in the ventral hippocampus and locomotor responses
to acute ketamine challenge. Neuropsychopharmacology 28, 1622–1632
(2003).
16. Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J. & Varney, M. A. Effects of
ketamine and N-methyl-D-aspartate on glutamate and dopamine release in
the rat prefrontal cortex: modulation by a group II selective metabotropic
glutamate receptor agonist LY379268. Neuroscience 117, 697–706 (2003).
17. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B. & Seeburg, P. H. Devel-
opmental and regional expression in the rat brain and functional properties of
four NMDA receptors. Neuron 12, 529–540 (1994).
18. Traynelis, S. F. et al. Glutamate receptor ion channels: structure, regulation,
and function. Pharmacol. Rev. 62, 405–496 (2010).
19. Paoletti, P., Bellone, C. & Zhou, Q. NMDA receptor subunit diversity: impact on
receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14,
383–400 (2013).
20. Preskorn, S. H. et al. An innovative design to establish proof of concept of the
antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate
antagonist, CP-101,606, in patients with treatment-refractory major depressive
disorder. J. Clin. Psychopharmacol. 28, 631–637 (2008).
21. Ibrahim, L. et al. A Randomized, placebo-controlled, crossover pilot trial
of the oral selective NR2B antagonist MK-0657 in patients with treatment-
resistant major depressive disorder. J. Clin. Psychopharmacol. 32, 551–557
(2012).
22. Boyce-Rustay, J. M. & Holmes, A. Genetic inactivation of the NMDA receptor
NR2A subunit has anxiolytic- and antidepressant-like effects in mice.
Neuropsychopharmacology 31, 2405–2414 (2006).
23. Jiménez-Sánchez, L., Campa, L., Auberson, Y. P. & Adell, A. The role of GluN2A
and GluN2B subunits on the effects of NMDA receptor antagonists in mod-
eling schizophrenia and treating refractory depression. Neuropsychopharma-
cology 39, 2673–2680 (2014).
24. Morris, P. J. et al. Synthesis and N-methyl-d-aspartate (NMDA) receptor activity
of ketamine metabolites. Org. Lett. 19, 4572–4575 (2017).
25. Auberson, Y. P. et al. 5-Phosphonomethylquinoxalinediones as competitive
NMDA receptor antagonists with a preference for the human 1A/2A, rather
than 1A/2B receptor composition. Bioorg. Med. Chem. Lett. 12, 1099–1102
(2002).
26. Puighermanal, E. et al. Dissociation of the pharmacological effects of THC by
mTOR blockade. Neuropsychopharmacology 38, 1334–1343 (2013).
27. Cryan, J. F., Valentino, R. J. & Lucki, I. Assessing substrates underlying the
behavioral effects of antidepressants using the modified rat forced swimming
test. Neurosci. Biobehav. Rev. 29, 547–569 (2005).
28. Frizelle, P. A., Chen, P. E. & Wyllie, D. J. A. Equilibrium constants for (R)-[(S)-1-(4-
bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-
methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A
and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of
synaptic transmission. Mol. Pharmacol. 70, 1022–1032 (2006).
Gordillo-Salas et al. Translational Psychiatry  (2018) 8:84 Page 8 of 9
29. Romero-Hernandez, A. & Furukawa, H. Novel mode of antagonist binding in
NMDA receptors revealed by the crystal structure of the GluN1-GluN2A
ligand-binding domain complexed to NVP-AAM077. Mol. Pharmacol. 92,
22–29 (2017).
30. Fischer, G. et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-
D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J.
Pharmacol. Exp. Ther. 283, 1285–1292 (1997).
31. Markova, B. et al. Novel pathway in Bcr-Abl signal transduction involves Akt-
independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway.
Oncogene 29, 739–751 (2010).
32. Harraz, M. M. & Snyder, S. H. Antidepressant actions of ketamine mediated by
the mechanistic target of rapamycin, nitric oxide, and Rheb. Neurotherapeutics
14, 728–733 (2017).
33. Zhang, K. et al. Essential roles of AMPA receptor GluA1 phosphorylation and
presynaptic HCN channels in fast-acting antidepressant responses of keta-
mine. Sci. Signal. 9, ra123 (2016).
34. Chourbaji, S. et al. AMPA receptor subunit 1 (GluR-A) knockout mice model
the glutamate hypothesis of depression. FASEB J. 22, 3129–3134 (2008).
35. Duric, V. et al. Altered expression of synapse and glutamate related genes in
post-mortem hippocampus of depressed subjects. Int. J. Neuropsycho-
pharmacol. 16, 69–82 (2013).
36. Martinez-Turrillas, R., Frechilla, D. & Del Río, J. Chronic antidepressant treatment
increases the membrane expression of AMPA receptors in rat hippocampus.
Neuropharmacology 43, 1230–1237 (2002).
37. Barbon, A. et al. Chronic antidepressant treatments induce a time-dependent
up-regulation of AMPA receptor subunit protein levels. Neurochem. Int. 59,
896–905 (2011).
38. Öngür, D., Drevets, W. C. & Price, J. L. Glial reduction in the subgenual pre-
frontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 95, 13290–13295
(1998).
39. Cotter, D., Mackay, D., Landau, S., Kerwin, R. & Everall, I. Reduced glial cell
density and neuronal size in the anterior cingulate cortex in major depressive
disorder. Arch. Gen. Psychiatry 58, 545–553 (2001).
40. Miguel-Hidalgo, J. J. et al. Glial fibrillary acidic protein immunoreactivity in the
prefrontal cortex distinguishes younger from older adults in major depressive
disorder. Biol. Psychiatry 48, 861–873 (2000).
41. Choudary, P. V. et al. Altered cortical glutamatergic and GABAergic signal
transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA
102, 15653–15658 (2005).
42. Banasr, M., Dwyer, J. M. & Duman, R. S. Cell atrophy and loss in depression:
reversal by antidepressant treatment. Curr. Opin. Cell Biol. 23, 730–737 (2011).
43. Banasr, M. & Duman, R. S. Glial loss in the prefrontal cortex is sufficient to
induce depressive-like behaviors. Biol. Psychiatry 64, 863–870 (2008).
44. Etiévant, A. et al. Astroglial control of the antidepressant-like effects of pre-
frontal cortex deep brain stimulation. EBioMedicine 2, 898–908 (2015).
45. Gasull-Camós, J., Tarrés-Gatius, M., Artigas, F. & Castañé, A. Glial GLT-1 blockade
in infralimbic cortex as a new strategy to evoke rapid antidepressant-like
effects in rats. Transl. Psychiatry 7, e1038 (2017).
46. Murrough, J. W., Abdallah, C. G. & Mathew, S. J. Targeting glutamate signalling
in depression: progress and prospects. Nat. Rev. Drug Discov. 16, 472–486
(2017).
47. Opazo, P., Sainlos, M. & Choquet, D. Regulation of AMPA receptor surface
diffusion by PSD-95 slots. Curr. Opin. Neurobiol. 22, 453–460 (2012).
48. Hackett, J. T. & Ueda, T. Glutamate release. Neurochem. Res. 40, 2443–2460
(2015).
49. Nichols, R. A., Chilcote, T. J., Czernik, A. J. & Greengard, P. Synapsin I regulates
glutamate release from rat brain synaptosomes. J. Neurochem. 58, 783–785
(1992).
50. Nibuya, M., Nestler, E. J. & Duman, R. S. Chronic antidepressant administration
increases the expression of cAMP response element binding protein (CREB) in
rat hippocampus. J. Neurosci. 16, 2365–2372 (1996).
51. Carlezon, W. A. Jr, Duman, R. S. & Nestler, E. J. The many faces of CREB. Trends
Neurosci. 28, 436–445 (2005).
52. Krishnan, V. & Nestler, E. J. The molecular neurobiology of depression. Nature
455, 894–902 (2008).
53. Martínez-Turrillas, R., Del Río, J. & Frechilla, D. Sequential changes in BDNF
mRNA expression and synaptic levels of AMPA receptor subunits in rat
hippocampus after chronic antidepressant treatment. Neuropharmacology 49,
1178–1188 (2005).
54. Narisawa-Saito, M., Carnahan, J., Arak, K., Yamaguchi, T. & Nawa, H. Brain-
derived neurotrophic factor regulates the expression of AMPA receptor
proteins in neocortical neurons. Neuroscience 88, 1009–1014 (1999).
Gordillo-Salas et al. Translational Psychiatry  (2018) 8:84 Page 9 of 9
